trending Market Intelligence /marketintelligence/en/news-insights/trending/ooq5vyqco1u4cg-vkynfew2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Eisai cancer drug approved as 1st-line treatment in Japan

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Eisai cancer drug approved as 1st-line treatment in Japan

Eisai Co. Ltd. said Treakisym was approved as a first-line treatment in Japan for patients with low-grade B-cell non-Hodgkin lymphoma and mantle cell lymphoma, or MCL, a cancer of white blood cells.

The drug will be used in combination with rituximab to treat patients. It is already approved as a monotherapy for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma and MCL.

Eisai began marketing Treakisym in late-2010 as part of a licensing agreement with SymBio Pharmaceuticals Ltd.